Skip to main content
JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults.
In February 2023, an expert consensus panel of pediatric and adult rheumatologists met to address challenges in Still’s disease (SD), including systemic juvenile idiopathic arthritis and adult-onset SD. They addressed four main topics: (1) early recognition and diagnosis of SD; (2) pathogenetic pathways and possible biomarkers for diagnosis and response; (3) refractory disease and risk factors, and (4) treatment of SD and its complications.
Retrospective EGPA study of mepolizumab Rx 45 pts Rx initially w/ 300 mg/4 weeks, 27% switched to 100 mg/4 wks a

Dr. John Cush RheumNow

1 year 3 months ago
Retrospective EGPA study of mepolizumab Rx 45 pts Rx initially w/ 300 mg/4 weeks, 27% switched to 100 mg/4 wks after 26 mos & 50% maintained complete remission without GC. Other half had sinonasal Sxs Rx w/ increased MEP dose orlocal therapy. https://t.co/H8ftg136Ez https://t.co/CKchbGpq20
Castleman disease (CD) is a rare, non-clonal lymphoproliferative disorder w/ systemic sxs & maybe linked w/ herpesvi

Dr. John Cush RheumNow

1 year 3 months ago
Castleman disease (CD) is a rare, non-clonal lymphoproliferative disorder w/ systemic sxs & maybe linked w/ herpesvirus 8, POEMS or TAFRO syndrome. Mimickers include lymphoma, sarcoma, IgG4-RD, Infections (EBV, HHV8, HIV, CMV, TB), Autoimmune Dz (RA, SLE, Stills) https://t.co/70sROoHusy
A nonrandomized, open-label, controlled trial has shown superior efficacy when baricitinib was given at night (instead of day); attesting to the benefits of chronotherapy - selective dosing meant to target the body's diurnal variations.
Hip replacement outcomes are not linked to OA severity, instead pts muscle quality before THA best predicts recovery aft

Dr. John Cush RheumNow

1 year 3 months ago
Hip replacement outcomes are not linked to OA severity, instead pts muscle quality before THA best predicts recovery after surgery. Imaging of 10 pts undergoing THA showed poor muscle quality predicted post-op performance/movement after surgery https://t.co/io0UXQl6n2 https://t.co/eI7u6BTPYx
Post-treatment Lyme Syndrome
  • EurekAlert!
Symptoms that persist long after Lyme disease is treated are not uncommon — a 2022 study found that 14% of patients who were diagnosed and treated early with antibiotic therapy would still develop Post Treatment Lyme Disease (PTLD). Yet doctors puzzle over the condition’s causes and how to help their patients through symptoms ranging from severe fatigue and cognitive challenges to body pain and arthritis.
RHEUMATOLOGISTS: What is your initial steroid dosing regimen w/ Class III/IV Lupus nephritis?

Dr. John Cush RheumNow

1 year 3 months ago
RHEUMATOLOGISTS: What is your initial steroid dosing regimen w/ Class III/IV Lupus nephritis?
ACR & Arthritis Foundation Denounce the Dismantling of Vital Health Programs

As organizations representing nearly

Dr. John Cush RheumNow

1 year 3 months ago
ACR & Arthritis Foundation Denounce the Dismantling of Vital Health Programs As organizations representing nearly 60 million adults and children living with arthritis in the United States and the rheumatologists and health care professionals who treat them, we are deeply https://t.co/VH3hPz115f
Diabetes Prevention with Hydroxychloroquine in Sjogren’s

A Taiwanese insurance claims analysis looked at HCQ use in

Dr. John Cush RheumNow

1 year 3 months ago
Diabetes Prevention with Hydroxychloroquine in Sjogren’s A Taiwanese insurance claims analysis looked at HCQ use in primary Sjögren syndrome (pSS) and showed that HCQ exposure significantly reduces the risk of new onset diabetes in pSS. Conversely, higher doses of https://t.co/WQD0RNfm5Z
An emulation trial shows that Humira biosimilars (Amjevita & Imraldi) were equivalent to Humira in psoriasis & a

Dr. John Cush RheumNow

1 year 3 months ago
An emulation trial shows that Humira biosimilars (Amjevita & Imraldi) were equivalent to Humira in psoriasis & achieving PASI <=2, both for new biologic starts and for biologic switchers. https://t.co/8lTGGs2rbP https://t.co/T6rTJ5ESj2
CDC's Committee on Immunization (ACIP) met and recommended:
1. Expand strains for meningococcal vax
2. Lower age for RSV

Dr. John Cush RheumNow

1 year 3 months ago
CDC's Committee on Immunization (ACIP) met and recommended: 1. Expand strains for meningococcal vax 2. Lower age for RSV vax > 50y 3. Rec. chikungunya vax for certain travelers - Flu & Covid Vax to be up next mtg 6/25 https://t.co/jInnR5JSxS https://t.co/PXg0HDLgnL https://t.co/Vro5mbjG9R
×